POS1345 PAIN OVER 5 YEARS IN OUR EARLY RHEUMATOID ARTHRITIS UCLOUVAIN BRUSSELS COHORT: RESULTS AND CORRELATION WITH CLINICAL RESPONSE, QUALITY OF LIFE

Background Pain is a major patient reported outcome in early rheumatoid patients (ERA). associated with disease activity but could be also related to non-inflammatory conditions. Chronic pain has negative impact on quality of life ERA patients. The main treatment objective remission or low control, relief priority patient. Objectives To evaluate the course and proportion unacceptable (VASp >4) during five-years follow-up investigate correlation clinical response life. Methods 474 fulfilling 2010 EULAR/ACR criteria included our UCLouvain Brussels cohort were retrospectively analyzed. All naïve csDMARDs (MTX), b- tsDMARDs symptoms duration < 12 months. was assessed using visual analogue scale (0-100 mm) defined as VAS > 40mm (VASp>4) based acceptable symptom state. VASp, HAQ DAS28-CRP scores at baseline (BL), 6, 12, 36 60 months order correlate % an (VASp>4), non (DAS28-CRP> 3.2) no restored (HAQ >0.5). Results Data from eligible collected. average age population 48.5 years, BMI 25.3. 70.5% are women. 27.1% smokers 68.8% positive for anti-citrullinated protein antibody (ACPA). evolution over 5 years shown Figure 1: 1. At BL, mean 60.2 +/- 26.5mm (range 0-100mm). VASp reduced by 45% (mean 33.1+/- 28.5 6 remained stable 51,7% reduction 29.0 +/-27.6mm) years. 78% (n=308) diagnosis which 40.4% (n=163) 33% year (Figure 2): 2. Clinical response: throughout No statistical difference observed age, sex ratio, BMI, ACPA, RF except (27.3% vs 15.6%) between not. A strong decrease pain, all-time points. Among months, BL score statistically higher (1.30 0.69 1.15 0.67), while similar (4.66 1.41 4.67 +/-1.24). We identified 20 follow-up, values increased (5.4 1.1 4.7 1.4 0.86 1.21 0.62). By contrast, 31 reached complete <4 + DAS28-CRP<3.2 HAQ< 0.5 follow up). Baseline lower this group. (38.9 28.4 61.9 25.7, 4.3 4.8 0.60 1.2 0.71). treated according standard care, mainly Methotrexate. Conclusion demonstrate that control achieved majority cohort. Decrease correlated score, meaning effect inflammation ERA. REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.